ECOR.NASDAQElectrocore, INC
10-Q: electroCore Reports Strong Revenue Growth in Q3 2024, Alleviating Going Concern Doubts
Sentiment:
Quarterly Report
electroCore, Inc. reports a 45% increase in net sales for the third quarter of 2024 compared to the same period last year, driven by growth across multiple channels.
Capital raiseThe company received net proceeds of approximately $9.0 million from the sale of securities during the nine months ended September 30, 2024.The company entered into a registered direct offering and concurrent private placements, which closed on June 5, 2024.The company received $1.0 million from the issuance of securities to its legal counsel.As of September 30, 2024, the company had approximately $11.6 million available of unused capacity under the 2022 Shelf Registration Statement, subject to a one-third limit.
Better than expectedThe company's net loss per share improved significantly in both the third quarter and the nine-month period compared to the previous year.The company's revenue growth of 45% in Q3 and 67% for the nine months ended September 30, 2024, is significantly higher than the previous year.The company's cash position has improved, alleviating previous concerns about its ability to continue as a going concern.
Summary
- electroCore, Inc. experienced a 45% increase in net sales for the three months ended September 30, 2024, reaching $6.554 million, compared to $4.508 million in the same period of 2023.
- The company's gross profit for the quarter was $5.489 million, with a gross margin of 84%.
- Operating expenses totaled $8.140 million, with research and development expenses decreasing to $0.521 million and selling, general, and administrative expenses increasing to $7.619 million.
- The net loss for the quarter was $2.497 million, or $0.31 per share, compared to a net loss of $4.032 million, or $0.68 per share, in the third quarter of 2023.
- For the nine months ended September 30, 2024, net sales were $18.136 million, a 67% increase compared to $10.839 million in the same period of 2023.
- The company's net loss for the nine-month period was $8.658 million, or $1.19 per share, compared to a net loss of $14.802 million, or $2.87 per share, in the same period of 2023.
- The company's cash, cash equivalents, and marketable securities totaled $13.2 million as of September 30, 2024.
- electroCore believes its current cash position will enable it to fund operations for at least the next 12 months, alleviating previous going concern doubts.
Sentiment
Score: 7
Explanation: The document shows a positive trend in revenue growth and reduced losses, which is encouraging. However, the company still faces risks and uncertainties, particularly regarding profitability and reliance on government contracts. The alleviation of going concern doubts is a significant positive.
Positives
- The company experienced significant revenue growth across multiple channels, including prescription gammaCore devices and non-prescription Truvaga products.
- The company's net loss per share improved significantly in both the third quarter and the nine-month period compared to the previous year.
- The company's cash position has improved, alleviating previous concerns about its ability to continue as a going concern.
- Gross margin remained strong at 84% for the third quarter and 85% for the nine-month period.
- Research and development expenses decreased significantly, indicating a focus on commercialization.
- The company secured a 10-year lease extension for its Rockaway, New Jersey facility, demonstrating long-term commitment.
Negatives
- The company continues to incur net losses, although the losses have decreased compared to the previous year.
- Selling, general, and administrative expenses increased, primarily due to higher variable selling and marketing costs.
- The company is still reliant on the VA/DoD for a significant portion of its revenue, which poses a concentration risk.
- The company's ability to sell certain gammaCore products into the government channel may be limited if the VA/DoD does not accept its application for a replacement FSS contract.
- The company's TAC-STIM revenue may fluctuate significantly from quarter to quarter.
Risks
- The company's future capital requirements are difficult to forecast and will depend on many factors outside of its control.
- If the company is unable to achieve its planned operating results or maintain sufficient financial resources, its business, financial condition, and results of operations may be materially and adversely affected.
- The company faces risks related to market acceptance of its gammaCore medical device, expansion into new therapeutic indications, and development of its wellness and human performance business.
- The company is subject to foreign currency exchange risks related to revenue and operating expenses in currencies other than the local currencies in which it operates.
- The company is subject to various claims, complaints, and legal actions in the normal course of business, including ongoing stockholder litigation.
Future Outlook
The company expects the majority of its remaining 2024 fiscal year revenue to come from the VA/DoD and U.S. channels. The company plans to continue investments in sales and marketing to support commercial efforts. The company believes its cash position will enable it to fund operations for at least the next 12 months.
Management Comments
- The company believes its cash, cash equivalents, marketable securities, and anticipated revenue will enable it to fund its operating expenses, working capital and capital expenditures as currently planned through 12 months from the date of the financial statements in this Quarterly Report.
- The company believes there may be large commercial opportunities for its gammaCore medical device with adoption by third-party payors, cash pay and physician dispense models, along with general wellness and human performance propositions through its Truvaga and TAC-STIM products.
Industry Context
The company's focus on non-invasive neuromodulation aligns with the growing trend in bioelectronic medicine. The company's products target conditions such as primary headache, general wellness, and human performance, which are areas of increasing interest in the healthcare and wellness industries. The company's reliance on government contracts, particularly with the VA/DoD, is a common strategy for medical device companies in the US.
Comparison to Industry Standards
- electroCore's revenue growth of 67% for the nine months ended September 30, 2024, is significantly higher than the average growth rate for medical device companies, which typically ranges from 5% to 15% annually. For example, companies like Medtronic and Abbott, while much larger, have seen single-digit growth in recent quarters.
- The company's gross margin of 85% is also relatively high compared to the industry average, which is typically between 60% and 75%. This suggests that electroCore has a strong pricing power or a cost-effective manufacturing process.
- However, electroCore's continued net losses are a concern, as many established medical device companies are profitable. For example, companies like Stryker and Boston Scientific consistently report positive net income.
- The company's reliance on the VA/DoD for a significant portion of its revenue is a risk, as government contracts can be subject to changes in policy and funding. Companies like Leidos and CACI, which also rely on government contracts, have diversified their revenue streams to mitigate this risk.
- electroCore's focus on non-invasive neuromodulation is a growing area in the medical device industry, with companies like Nevro and Axonics also developing similar technologies. However, these companies have a more established market presence and a broader range of products.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Consultant | Chief Financial Officer | Brian M. Posner | 2024-10-04 | Retirement from CFO role |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Bylaw Amendment | The board of directors approved and adopted the second amended and restated bylaws of the Company, which amend certain of the provisions of Article III, Sections 5(B)(1), (B)(4), (B)(5), (F), and (G). Among other things, the amendments set forth in the Amended and Restated Bylaws (i) address provisions of the universal proxy rules adopted by the SEC, by clarifying that to comply with such rules, stockholders who intend to solicit proxies in support of a director nominee other than the Boards nominees must provide a notice to the Company that sets forth the information required by Rule 14a-19 under the Exchange Act, including with respect to applicable notice and solicitation requirements, and that the Company shall disregard any proxies or votes solicited for such stockholders nominee(s) by any such stockholder who fails to comply with Rule 14a-19; (ii) specify the process and disclosure requirements for a stockholder submitting notice of a director nomination with respect to, among other things, (x) the dates of first contact between the proposed director and the stockholder nominee; (y) known financial supporters of the proposed director; and (z) a form of questionnaire and form of nominee's representation and agreement that must be delivered to the Company and requiring that such items, completed by the nominee, be delivered to the Company along with such notice of a director nomination; and (iii) require that a stockholder directly or indirectly soliciting proxies from other stockholders use a proxy card color other than white. | 2024-11-13 | The amendments are intended to ensure compliance with SEC rules and to provide clarity and transparency in the director nomination process. |
Legal Proceedings
- The company is subject to ongoing stockholder litigation, with the plaintiffs having filed a notice of appeal to the United States Court of Appeals for the Third Circuit.
- The company intends to continue to vigorously defend itself in these matters.
- The company is not aware of any further currently pending litigation for which it believes the outcome could have a material adverse effect on its operations or financial position.
Related Party Transactions
- On October 4, 2024, the Company and a former executive entered into a consulting agreement.
- On July 11, 2024, the Company and a member of its board of directors entered into a consulting agreement.
Stakeholder Impact
- Shareholders will be impacted by the company's financial performance and any potential dilution from future capital raises.
- Employees will be impacted by the company's ability to continue operations and any changes in compensation or benefits.
- Customers will be impacted by the company's ability to continue providing its products and services.
- Suppliers will be impacted by the company's ability to pay for goods and services.
- Creditors will be impacted by the company's ability to repay its debts.
Next Steps
- The company will continue its investments to expand its efforts in various channels and markets in 2024 and beyond.
- The company will continue to work with the appropriate government personnel to replace its existing FSS contract.
- The company expects NICE to review the guidance document and any changes in recommendation or pricing may adversely impact its ability to work with NHS England on the MTFM program.
Key Dates
| Date | Description |
|---|---|
| 2020-07-17 | Date of original class action lawsuit. |
| 2022-04-01 | Date of corporate credit card arrangement with Citibank, N.A. |
| 2023-01-01 | Start of various reporting periods. |
| 2023-03-13 | Date of filing of the company's Annual Report on Form 10-K. |
| 2023-07-01 | Start of various reporting periods. |
| 2023-07-31 | Date of closing of registered direct offering and concurrent private placements. |
| 2023-09-30 | End of the reporting period for the third quarter of 2023. |
| 2023-12-31 | End of the reporting period for the year 2023. |
| 2024-01-01 | Start of various reporting periods. |
| 2024-02-06 | Date of The First Amendment to Lease Agreement. |
| 2024-03-06 | Date the company received a net cash payment of $122,000 from the sale of its New Jersey state net operating losses. |
| 2024-03-31 | End of the reporting period for the first quarter of 2024. |
| 2024-04-01 | Start of various reporting periods. |
| 2024-05-01 | Effective date of the Rockaway Amendment. |
| 2024-05-31 | Date of private placement agreements with certain institutional and accredited investors and directors of the Company. |
| 2024-06-01 | Commencement date of the expansion space lease. |
| 2024-06-03 | Date of securities purchase agreement with an institutional accredited investor. |
| 2024-06-05 | Date of closing of registered direct offering and concurrent private placements. |
| 2024-06-30 | End of the reporting period for the second quarter of 2024. |
| 2024-07-01 | Start of various reporting periods. |
| 2024-07-02 | Date the company entered into a Commercial Insurance Premium Finance and Security Agreement. |
| 2024-07-11 | Date of consulting agreement with a member of the board of directors. |
| 2024-07-31 | Expiration date of the Rockaway, New Jersey lease. |
| 2024-09-30 | End of the reporting period for the third quarter of 2024. |
| 2024-10-04 | Date of consulting agreement with a former executive. |
| 2024-10-09 | Date the court advised it will decide the appeal on the papers and will not hear oral argument. |
| 2024-11-07 | Date of share count. |
| 2024-11-13 | Date of adoption of the second amended and restated bylaws. |
Keywords
gammaCore, Truvaga, TAC-STIM, nVNS, bioelectronic medicine, neuromodulation, revenue, net loss, VA/DoD, medical devices, healthcare, financial results, stockholders, operating expenses
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.